

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 501/36, A61K 31/545	A1	(11) International Publication Number: WO 96/26209 (43) International Publication Date: 29 August 1996 (29.08.96)
(21) International Application Number: PCT/GB96/00373 (22) International Filing Date: 19 February 1996 (19.02.96) (30) Priority Data: 9503717.2 24 February 1995 (24.02.95) GB (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): WEBSTER, Richard, Andrew, Bentley [GB/GB]; Pfizer Limited, Pfizer Central Research, Sandwich, Kent CT13 9NJ (GB). (74) Agent: STEVENS, Ian, Edward; Stevens Hewlett & Perkins, 1 St Augustine's Place, Bristol BS1 4UD (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: STABLE HYDRATES OF A CEPHALOSPORIN CHLORIDE SALT (57) Abstract The cephalosporin compound [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride is provided as a mono-, di- or tri-hydrate. The hydrates are produced by treating an aqueous solution of the corresponding carboxylate with hydrogen chloride and have been found to possess unexpectedly superior stability properties over other forms of the compound. The hydrates may be used in the treatment and/or prevention of bacterial infections in humans and animals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

STABLE HYDRATES OF A CEPHALOSPORIN CHLORIDE SALT

5 The present invention relates to a novel compound, to a process for its manufacture and to its use in the treatment and/or prevention of bacterial infections in humans and animals caused by a wide range of organisms.

10 EP-A-0 416 814 (Beecham Group plc) describes certain cephalosporin compounds which are described to be useful in the treatment of bacterial infections in humans and animals caused by a wide range of organisms.

One particular compound mentioned therein, ie, [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate (ie, example 2) has now been prepared as crystalline carboxylic acid chloride hydrochloride mono-, di- or tri-hydrate.

15 This particular form of the compound has unexpectedly superior stability properties over the freeze dried material of example 2 in EP-A-0416814.

20 Accordingly the present invention provides [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride as a mono, di or tri-hydrate.

25 Preferably the present invention provides [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride as a tri-hydrate.

30 The present invention further provides a process for the preparation of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride as a mono, di or tri-hydrate said process comprising treating an aqueous solution of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate with hydrogen chloride

35 Suitably [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate is dissolved in water and treated with aqueous hydrochloric acid for example a 2 molar solution thereof. The resulting solution is suitably diluted with a water soluble organic solvent to precipitate the product; for example tetrahydrofuran. The resulting mixture may
40 then be cooled for example overnight to 0 to 5°C, suitably at around 4°C. The resulting crystalline product may then be isolated for example by filtration, and dried for example in vacuo at ambient temperature.

45 It should be appreciated that more rigorous drying conditions will remove the bound molecules of water of hydration. In this way drying conditions may be conventionally controlled to give [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride as the mono, di or tri-hydrates.

50 [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate may be prepared according to the procedures mentioned in or outlined by EP-A-416 814.

55 It should be appreciated that [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate is an active medicinal product and may be formulated into unit dose forms suitable for administration to humans or animals in need of treatment.

60 [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate is especially suitable for the treatment and/or prevention of bacterial diseases in animals.

65 Such unit dose forms may be for example those contemplated in EP-A-416 814 and those generally known in the art, especially those particularly adapted for administration to animals.

70 Amounts of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate suitable for formulation into a unit dose form and the number of unit dose forms administered to a human or animal patient is mentioned in EP-A-0 416 814 and is hereincorporated by reference.

75 The types of bacterial infections which may be treated by [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate include those specifically mentioned in EP-A-416 814 which are incorporated herein by reference. Such infections are hereinafter referred to as "the infections".

80 The present invention therefore provides a method for the treatment and/or prevention of "the infections" which comprises administering an effective amount of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride
85 hydrochloride mono, di or tri-hydrate to a sufferer in need thereof.

90 The present invention also provides the use of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate in the treatment and/or prevention of "the infections" in humans or animals.

95 The present invention also provides the use of [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate in the manufacture of a medicament for treating and/or preventing "the infections" in humans or animals.

100 The present invention also provides a pharmaceutical composition for use in the treatment and/or prevention of "the infections" in animals or humans which comprises admixing [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono, di or tri-hydrate with pharmaceutically acceptable excipients.

105 The following example illustrates the present invention.

Example 1

[6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride trihydrate

110 [6R,7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate (2.75g, 5.1mmol) was dissolved in H₂O (10mL) and acidified with 2M aqueous HCl (15mL). The solution was diluted with THF (400mL) and the mixture stored at 4°C overnight. The resulting crystalline material was collected by filtration, washed with THF (100mL) and dried *in vacuo* at 20°C. The *title compound* (2.7g) was isolated as a crystalline solid (needles): δ (DMSO-d₆) 2.99(s, 3H), 3.55(d, J=18Hz, 1H), 3.80(d, J=18Hz, 1H), 3.95(s, 3H), 4.41(q, J=12.9Hz, 2H), 5.24(d, J=4.8Hz, 1H), 5.79(d.d, J=7.9Hz, 4.8Hz, 1H), 6.96(s, 1H), 8.01(d, J=7.3Hz, 2H), 8.92(d, J=7.2Hz, 2H), 9.87(d, J=7.9Hz, 1H); H₂O 8.9% (Theory 8.16%).

115

120

CLAIMS

1. [6R, 7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid
5 chloride hydrochloride as a mono-, di-, or tri- hydrate.
2. [6R, 7R]-7-[2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid
10 chloride hydrochloride as a tri-hydrate.
3. A process for the preparation of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-
15 ceph-3-em-4-carboxylic acid chloride hydrochloride as a mono-, di or tri-hydrate, said process comprising treating an aqueous solution of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylate with hydrogen chloride.
20
4. The use of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono-, di- or tri-hydrate in the
25 manufacture of a medicament for treating and/or preventing bacterial infections in humans or animals.
5. A pharmaceutical composition for use in the treatment and/or
30 prevention of bacterial infections in humans or animals which comprises an admixture of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono-, di- or tri-hydrate with
35 pharmaceutically acceptable excipients.

6. A method for the treatment and/or prevention of bacterial infections in humans or animals which comprises administering an effective amount of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono-, di- or tri-hydrate to a sufferer in need thereof.
7. The use of [6R, 7R]-7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido]-3-[1-(methylamino)pyridinium-4-thiomethyl]-ceph-3-em-4-carboxylic acid chloride hydrochloride mono-, di- or tri-hydrate in the treatment and/or prevention of bacterial infections in humans or animals.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/GB 96/00373

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D501/36 A61K31/545

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 416 814 (BEECHAM GROUP PLC) 13 March 1991 cited in the application see example 54, page 68 ---	1-7
A	EP,A,0 638 573 (LUCKY LTD) 15 February 1995 see the whole document ---	1-7
A	US,A,4 146 710 (NAITO KENZO ET AL) 27 March 1979 see the whole document -----	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 May 1996

Date of mailing of the international search report

04.06.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No

PCT/GB 96/00373

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0416814	13-03-91	AU-B- 635561	25-03-93
		AU-B- 6210690	07-03-91
		CA-A- 2024399	05-03-91
		CN-A- 1050023	20-03-91
		JP-A- 3118381	20-05-91
		US-A- 5504076	02-04-96
EP-A-0638573	15-02-95	NONE	
US-A-4146710	27-03-79	JP-C- 1281844	27-09-85
		JP-A- 53029913	20-03-78
		JP-B- 60003314	26-01-85
		BE-A- 858296	28-02-78
		BG-B- 60439	31-03-95
		CA-A- 1102310	02-06-81
		CH-A- 630088	28-05-82
		DE-A- 2738711	02-03-78
		FR-A,B 2364922	14-04-78
		GB-A- 1589841	20-05-81
		NL-A- 7709614	02-03-78
		SE-A- 7709745	01-03-78